Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study

scientific article

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/00126334-200404150-00007
P698PubMed publication ID15021314

P2093author name stringLeonardo Calza
Roberto Manfredi
Francesco Chiodo
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectnevirapineQ263713
efavirenzQ422645
P304page(s)492-502
P577publication date2004-04-01
P1433published inJournal of Acquired Immune Deficiency SyndromesQ6294722
P1476titleEfavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study
P478volume35

Reverse relations

cites work (P2860)
Q36305444A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women
Q57000612Antiretroviral Therapy in the Real World : Population-Based Pharmacoeconomic Analysis of Administration of Anti-HIV Regimens to 990 Patients
Q26852974Antiretroviral medication: an emerging category of prescription drug misuse
Q81433325Antiretroviral-associated Hepatotoxicity
Q37252113Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults
Q37002481Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults
Q37163343Current and future antiretroviral treatment options in paediatric HIV infection
Q37139458EFV/FTC/TDF-associated hepatotoxicity: a case report and review
Q34143084Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth
Q30240127Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals
Q24235724Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals
Q36723853Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
Q36787311Efavirenz: a review
Q46879488Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia
Q36276597Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
Q43179922Etravirine in first-line therapy
Q37322060Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic
Q43040351Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients
Q36718901Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
Q36286145Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan
Q36762436Neuropsychiatric side effects of efavirenz therapy
Q27021762Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis
Q37816389Pediatric antiretroviral therapy
Q46923095Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine
Q51547763Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Q44513458Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
Q43179914Role of etravirine in combination antiretroviral therapy
Q37950517Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children

Search more.